Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | THRA | P10827 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | RARB | P10826 | 1/20 | 0.48 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 2/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | TACR2 | P21452 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26660483 | 0.91 | ESR1 (0.59) | ALDH1A1HSD17B10CA2THRATHRB | |
| SCHEMBL11141986 | 0.91 | ESR1 (0.59) | ALDH1A1HSD17B10CA2THRATHRB | |
| SCHEMBL28400146 | 0.91 | ESR1 (0.59) | ALDH1A1HSD17B10CA2THRATHRB | |
| SCHEMBL2554463 | 0.86 | THRB (0.48) | ALDH1A1CA2THRBPLK1KDM4E | |
| SCHEMBL8161742 | 0.84 | ALDH1A1 (0.52) | ALDH1A1HSD17B10HPGDCA2SMN1; SMN2 | |
| SCHEMBL5074036 | 0.84 | TSHR (0.54) | ALDH1A1HSD17B10HPGDCA2SMN1; SMN2 | |
| Formic Acid SCHEMBL28060935 | 0.84 | ALDH1A1 (0.61) | ALDH1A1HSD17B10HPGDCA2SMN1; SMN2 | |
| SCHEMBL83869 | 0.83 | CA2 (0.65) | ALDH1A1HSD17B10HPGDCA2SMN1; SMN2 | |
| SCHEMBL1610164 | 0.80 | CA2 (0.48) | ALDH1A1HSD17B10HPGDCA2SMN1; SMN2 | |
| SCHEMBL219423 | 0.80 | ALDH1A1 (0.52) | ALDH1A1HSD17B10HPGDCA2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649184-A1 | SILICONE COMPOUNDS | The Procter and Gamble Company (US) | 2020-05-13 | — | — | EP | claimed |
| EP-3649183-A1 | SILICONE COMPOUNDS | The Procter and Gamble Company (US) | 2020-05-13 | — | — | EP | claimed |
| WO-2019010263-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2019-01-10 | — | — | WO | claimed |
| WO-2019010265-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2019-01-10 | — | — | WO | claimed |
| EP-3649184-A1 | SILICONE COMPOUNDS | The Procter and Gamble Company (US) | 2020-05-13 | — | — | EP | disclosed |
| EP-3649183-A1 | SILICONE COMPOUNDS | The Procter and Gamble Company (US) | 2020-05-13 | — | — | EP | disclosed |
| WO-2019010265-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2019-01-10 | — | — | WO | disclosed |
| WO-2019010263-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2019-01-10 | — | — | WO | disclosed |
| US-7696238-B2 | Substituted benzo[d]isoxazol-3-yl amine compounds as analgesics | GRUENENTHAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-7696238-B2 | Substituted benzo[d]isoxazol-3-yl amine compounds as analgesics | GRUENENTHAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-20080176915-A1 | Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics | GRUENENTHAL GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176915-A1 | Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics | GRUENENTHAL GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20050080058-A1 | New vitamin D derivatives with carbo-or heterocyclic substituents at C-25, a process for their production, intermediate products and their use for producing medicaments | SCHERING AKTIENGESELLSCHAFT PATENTS (DE) | 2005-04-14 | — | — | US | disclosed |
| CN-1173944-C | Vitamin D-derivatives having a carbocyclic or heterocyclic substituent at C-25, method for the production thereof, intermediate products and use thereof for producing medicaments | ���ֹɷݹ�˾ | 2004-11-03 | — | — | CN | disclosed |
| US-6642218-B2 | (5Z,7E,22E)-(1S,3R,24R)-25-(5-Propyloxazol-2-yl)-26,27-cyclo -9,10-secocholesta-5,7,10(19), 22-tetraene-1,3,24-triol for treatment of diseases characterized by hyperproliferation and deficient cell differentiation | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-11-04 | — | — | US | disclosed |
| EP-0900198-B1 | NEW VITAMIN D DERIVATIVES WITH CARBO- OR HETEROCYCLIC SUBSTITUENTS AT C-25, A PROCESS FOR THEIR PRODUCTION, INTERMEDIATE PRODUCTS AND THEIR USE FOR PRODUCING MEDICAMENTS | SCHERING AG (DE) | 2003-03-12 | — | — | EP | disclosed |
| US-20020049344-A1 | NEW VITAMIN D DERIVATIVES WITH CARBO-OR HETEROCYCLIC SUBSTITUENTS AT C-25, A PROCESS FOR THEIR PRODUCTION, INTERMEDIATE PRODUCTS AND THEIR USE FOR PRODUCING MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-04-25 | — | — | US | disclosed |
| CN-1216978-A | Vitamin D-derivatives having a carbocyclic or heterocyclic substituent at C-25, method for the production thereof, intermediate products and use thereof for producing medicaments | SCHERING AG (DE) | 1999-05-19 | — | — | CN | disclosed |
| EP-0900198-A1 | NEW VITAMIN D DERIVATIVES WITH CARBO- OR HETEROCYCLIC SUBSTITUENTS AT C-25, A PROCESS FOR THEIR PRODUCTION, INTERMEDIATE PRODUCTS AND THEIR USE FOR PRODUCING MEDICAMENTS | Schering Aktiengesellschaft (DE) | 1999-03-10 | — | — | EP | disclosed |
| WO-1997041096-A1 | NEW VITAMIN D DERIVATIVES WITH CARBO- OR HETEROCYCLIC SUBSTITUENTS AT C-25, A PROCESS FOR THEIR PRODUCTION, INTERMEDIATE PRODUCTS AND THEIR USE FOR PRODUCING MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049344-A1 | NEW VITAMIN D DERIVATIVES WITH CARBO-OR HETEROCYCLIC SUBSTITUENTS AT C-25, A PROCESS FOR THEIR PRODUCTION, INTERMEDIATE PRODUCTS AND THEIR USE FOR PRODUCING MEDICAMENTS | CYP2R1, VDR, CYP24A1 | ALDH1A1 613/4885HSD17B10 252/4885HPGD 43/4885 |
| US-20080176915-A1 | Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics | KCNQ1, KCNQ2, KCNQ3 | ALDH1A1 1965/4885HSD17B10 3447/4885HPGD 2090/4885 |
| US-20050080058-A1 | New vitamin D derivatives with carbo-or heterocyclic substituents at C-25, a process for their production, intermediate products and their use for producing medicaments | VDR, CYP24A1, CYP2R1 | ALDH1A1 3086/4885HSD17B10 988/4885HPGD 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.